HPRA Drug Safety Newsletter Edition 93
Download:
hpra-drug-safety-newsletter-edition-93.pdf
259 KB
The latest edition of the HPRA Drug Safety Newsletter includes important updates to support the safe and appropriate use of the following medicines:
Domperidone-containing medicines: No longer approved for use in children due to lack of efficacy.
Direct oral anticoagulants (DOACs) are not recommended in patients with antiphospholipid syndrome (APS) due to possible increased risk of recurrent thrombotic events.
Use of Xeljanz (tofacitinib) restricted in patients at high risk of pulmonary embolism while European Medicines Agency (EMA) review is ongoing.
« Back